The Phase 3 Trials of Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease

Sang Hyoung Park

doi:10.4166/kjg.2017.69.1.90

Journal List > Korean J Gastroenterol > v.69(1) > 1007674

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Park: The Phase 3 Trials of Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease

Research Update

Korean J Gastroenterol 2017;69(1):90-91.

Published online: 4 October 2017

DOI: https://doi.org/10.4166/kjg.2017.69.1.90

The Phase 3 Trials of Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease

Sang Hyoung Park

Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Correspondence to: Sang Hyoung Park, Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. Tel: +82-2-3010-5768; Fax: +82-2-476-0824; E-mail: shpark78@amc.seoul.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease

References

1. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016; 14:111–119.

2. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369:1641–1657.

3. Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with metaanalysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2017; 45:3–13.

4. Singh S, Pardi DS. Update on anti-tumor necrosis factor agents in Crohn disease. Gastroenterol Clin North Am. 2014; 43:457–478.

5. Swoger JM, Regueiro M. Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops. Inflamm Bowel Dis. 2014; 20:926–935.

6. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013; 369:711–721.

7. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016; 375:1946–1960.

8. Papp KA, Griffiths CE, Gordon K, et al. Longterm safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013; 168:844–854.

9. Papp K, Gottlieb AB, Naldi L, et al. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015; 14:706–714.

10. Park SH, Yang SK, Park SK, et al. Longterm prognosis of crohn's disease and its temporal change between 1981 and 2012: a hos-pital-based cohort study from Korea. Inflamm Bowel Dis. 2014; 20:488–494.

11. Park SH, Hwang SW, Kwak MS, et al. Longterm outcomes of infliximab treatment in 582 Korean patients with Crohn's disease: a hospital-based cohort study. Dig Dis Sci. 2016; 61:2060–2067.

12. Loftus EV, Augustin M, Bissonnette R, et al. Prevalence of inflammatory bowel disease among patients with psoriasis and incidence of serious infections in this subset: results from the PSOLAR registry. Gastroenterology. 2016; 150(4 Suppl 1):S805.

13. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2014; 63:88–95.

TOOLS

Similar articles